Vireo Growth (VREOF) Operating Expenses (2020 - 2026)
Vireo Growth (VREOF) reported Operating Expenses of $50.3 million for Q1 2026, up 383.65% on a YoY basis from $10.4 million in Q1 2025, and down 14.31% sequentially from $58.7 million in Q4 2025.
Vireo Growth (VREOF) Operating Expenses (2020 - 2026) Analysis & Trends
Vireo Growth (VREOF) has 7 years of Operating Expenses data on file, last reported at $50.3 million in Q1 2026.
- For the quarter ending Q1 2026, Operating Expenses rose 383.65% year-over-year to $50.3 million; the trailing twelve-month figure through Mar 2026 stood at $168.0 million (up 318.73% YoY), and the FY2025 full-year result was $128.1 million, up 244.4% from the prior year.
- Operating Expenses declined to $50.3 million in Q1 2026, from $58.7 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $58.7 million in Q4 2025 to a low of $6.7 million in Q4 2023.
- A 5-year average of $16.9 million and a median of $10.1 million in 2022 frame the typical range for Operating Expenses.
- Across the five-year window, Operating Expenses fell 25.23% in 2024 and soared 383.65% in 2026, its largest moves.
- Tracing VREOF's Operating Expenses over 5 years: stood at $7.8 million in 2022, then fell by 14.59% to $6.7 million in 2023, then soared by 102.2% to $13.5 million in 2024, then jumped by 335.0% to $58.7 million in 2025, then dropped by 14.31% to $50.3 million in 2026.
- Business Quant data shows VREOF's Operating Expenses at $50.3 million in Q1 2026, $58.7 million in Q4 2025, and $36.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 1.00 Bn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 788.00 Mn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | 12.58 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 455.70 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 1.24 Bn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 621.10 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 494.00 Mn |
| 10 | Vireo Growth | 10.53 Bn | 10.38 Bn | 59.30 Mn | 50.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 50.30 Mn |
| Dec 31, 2025 | 58.70 Mn |
| Sep 30, 2025 | 36.57 Mn |
| Jun 30, 2025 | 22.44 Mn |
| Mar 31, 2025 | 10.40 Mn |
| Dec 31, 2024 | 13.49 Mn |
| Sep 30, 2024 | 8.47 Mn |
| Jun 30, 2024 | 7.76 Mn |
| Mar 31, 2024 | 7.48 Mn |
| Dec 31, 2023 | 6.67 Mn |
| Sep 30, 2023 | 7.33 Mn |
| Jun 30, 2023 | 10.37 Mn |
| Mar 31, 2023 | 9.15 Mn |
| Dec 31, 2022 | 7.81 Mn |
| Sep 30, 2022 | 9.73 Mn |
| Jun 30, 2022 | 10.06 Mn |
| Mar 31, 2022 | 10.25 Mn |
| Dec 31, 2021 | 10.41 Mn |
| Sep 30, 2021 | 9.25 Mn |
| Jun 30, 2021 | 10.16 Mn |